Firebrick Pharma Limited (AU:FRE) has released an update.
Firebrick Pharma Limited has announced a strategic partnership with Keith Shortall, a former executive of J&J Consumer Health APAC, to expand the Singaporean distribution of their Nasodine nasal spray, with a view to further Southeast Asian market penetration. Shortall brings extensive regional experience and is incentivized with share options tied to distribution milestones by June 2025. The company, known for innovating with povidone-iodine formulations, has successfully launched Nasodine in the United States and Singapore and is looking to advance its commercial presence in international markets.
For further insights into AU:FRE stock, check out TipRanks’ Stock Analysis page.
